Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Alendronic acid
Drug ID BADD_D00066
Description Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label][A959].
Indications and Usage Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone[FDA Label][A959,A176750]. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min[FDA Label].
Marketing Status approved
ATC Code M05BA04
DrugBank ID DB00630
KEGG ID D07119
MeSH ID D019386
PubChem ID 2088
TTD Drug ID D09KLR
NDC Product Code Not Available
UNII X1J18R4W8P
Synonyms Alendronate | 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate | Aminohydroxybutane Bisphosphonate | MK-217 | MK 217 | MK217 | Alendronate Monosodium Salt, Trihydrate | Alendronate Sodium | Fosamax
Chemical Information
Molecular Formula C4H13NO7P2
CAS Registry Number 66376-36-1
SMILES C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Macular degeneration06.09.03.0010.000418%Not Available
Malaise08.01.01.003--
Malignant hypertension24.08.01.0020.000044%Not Available
Malignant melanoma23.08.01.001; 16.03.01.0010.000176%Not Available
Mass08.03.05.0030.000242%Not Available
Mastication disorder07.01.06.016; 15.03.05.022; 17.05.03.0060.000154%Not Available
Melaena24.07.02.013; 07.12.02.004--Not Available
Melanocytic naevus23.10.01.007; 16.26.01.0070.000154%Not Available
Memory impairment17.03.02.003; 19.20.01.0030.000427%
Meniere's disease17.02.12.003; 07.01.07.007; 04.04.02.0030.000066%Not Available
Meningioma17.20.01.005; 16.30.01.0050.000066%Not Available
Menopause26.03.01.001--Not Available
Mental impairment19.21.02.003; 17.03.03.0020.000110%Not Available
Metastases to spine16.22.02.007; 15.09.03.0070.000044%Not Available
Micturition urgency20.02.02.0060.000273%
Migraine24.03.05.003; 17.14.02.0010.001087%Not Available
Mitral valve incompetence02.07.01.0020.000704%Not Available
Mouth cyst16.05.04.002; 07.20.02.0020.000066%Not Available
Mouth haemorrhage24.07.02.014; 07.05.02.0010.000132%
Mouth ulceration07.05.06.0040.000154%Not Available
Movement disorder17.01.02.0100.000229%Not Available
Mucosal ulceration08.01.06.0030.000088%Not Available
Multiple sclerosis10.04.10.008; 17.16.01.0010.000110%Not Available
Muscle atrophy17.05.03.004; 15.05.03.0030.000220%Not Available
Muscle disorder15.05.03.0140.000088%Not Available
Muscle spasms15.05.03.0040.002157%
Muscular weakness17.05.03.005; 15.05.06.0010.001506%
Musculoskeletal pain15.03.04.0070.002074%
Myalgia15.05.02.0010.003504%
Myasthenia gravis17.05.04.001; 15.05.08.001; 10.04.05.0010.000044%
The 14th Page    First    Pre   14 15 16 17 18    Next   Last    Total 39 Pages